Brokerages expect that Waters Co. (NYSE:WAT) will report $670.98 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Waters’ earnings, with the lowest sales estimate coming in at $663.20 million and the highest estimate coming in at $673.00 million. Waters reported sales of $628.79 million during the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The business is expected to announce its next earnings report before the market opens on Tuesday, January 23rd.

According to Zacks, analysts expect that Waters will report full-year sales of $670.98 million for the current year, with estimates ranging from $2.29 billion to $2.30 billion. For the next financial year, analysts anticipate that the firm will report sales of $2.43 billion per share, with estimates ranging from $2.40 billion to $2.45 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Waters.

Waters (NYSE:WAT) last released its quarterly earnings data on Tuesday, October 24th. The medical instruments supplier reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.03. Waters had a net margin of 24.34% and a return on equity of 23.61%. The business had revenue of $565.58 million during the quarter, compared to analyst estimates of $555.25 million. During the same quarter in the previous year, the business earned $1.57 EPS. Waters’s quarterly revenue was up 7.4% compared to the same quarter last year.

Several equities research analysts recently issued reports on WAT shares. Deutsche Bank lifted their price objective on shares of Waters from $199.00 to $200.00 and gave the company a “hold” rating in a research note on Wednesday, October 25th. Bank of America lifted their price objective on shares of Waters from $192.00 to $202.00 and gave the company a “neutral” rating in a research note on Friday, November 10th. Barclays lifted their price objective on shares of Waters from $188.00 to $193.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Waters from a “hold” rating to a “buy” rating and set a $211.00 price objective for the company in a research note on Monday, October 23rd. Finally, Cowen reaffirmed a “hold” rating and issued a $190.00 price objective on shares of Waters in a research note on Friday, November 3rd. Eleven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $197.33.

In other Waters news, SVP Elizabeth B. Rae sold 12,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $197.95, for a total transaction of $2,375,400.00. Following the completion of the transaction, the senior vice president now owns 18,129 shares of the company’s stock, valued at approximately $3,588,635.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas P. Salice sold 3,500 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $200.03, for a total transaction of $700,105.00. Following the transaction, the director now directly owns 20,349 shares of the company’s stock, valued at approximately $4,070,410.47. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,159 shares of company stock valued at $18,412,172. Company insiders own 5.07% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its holdings in shares of Waters by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 209,081 shares of the medical instruments supplier’s stock worth $38,436,000 after purchasing an additional 1,448 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Waters during the 3rd quarter worth about $3,446,000. Advisory Services Network LLC increased its holdings in shares of Waters by 6.0% during the 2nd quarter. Advisory Services Network LLC now owns 1,145 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 65 shares during the period. UBS Asset Management Americas Inc. increased its holdings in shares of Waters by 46.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 374,472 shares of the medical instruments supplier’s stock worth $68,843,000 after purchasing an additional 119,130 shares during the period. Finally, Nippon Life Insurance Co. bought a new position in shares of Waters during the 3rd quarter worth about $819,000. 92.13% of the stock is owned by hedge funds and other institutional investors.

Shares of Waters (NYSE:WAT) opened at $209.16 on Thursday. The company has a quick ratio of 5.71, a current ratio of 6.16 and a debt-to-equity ratio of 0.66. Waters has a 52 week low of $137.72 and a 52 week high of $211.65. The stock has a market cap of $16,617.63, a price-to-earnings ratio of 30.85, a P/E/G ratio of 2.80 and a beta of 0.82.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/18/670-98-million-in-sales-expected-for-waters-co-wat-this-quarter.html.

About Waters

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.